9月21日，百奥赛图-B盘中上涨9.63%，报67.15港元/股，成交额2.05亿港元。
消息面上，AI制药政策与产业合作催化密集落地，CXO板块景气度明确上行。公司上半年实现营收9.41亿元，同比增长51.6%；归母净利润2.41亿元，同比大增402.3%；毛利率由74.4%提升至79.3%。其中临床前板块营收7.23亿元，同比增长57.9%，创新动物模型销售收入4.46亿元，同比增长62.4%；抗体发现业务收入2.18亿元，毛利率达92.8%。此外，公司近期与齐鲁制药达成全人纳米抗体分子非排他授权合作，RenMice平台商业化进入加速兑现期。机构指出，AIDD有望重塑早期药物发现流程，公司凭借技术闭环与全球化布局有望持续受益。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.